Novartis' New SMA Gene Therapy Cleared in EU

Novartis spinal muscular atrophy drug approved in EU (NVS:NYSE)

Novartis (NVS) stock is in focus as the firm wins the EU nod for Itvisma gene therapy for children aged two years and older with spinal muscular atrophy. Read more here.

Novartis' new SMA gene therapy cleared in EU

Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults  Fixed, one-time dose designed to replace the...

European Commission approves Novartis’ Itvisma to treat SMA

The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.The post European Commission approves Novartis’ Itvisma to treat SMA appeared first on Hospital Management.

Novartis receives European Commission approval for Itvisma for spinal muscular atrophy

EC backs first gene replacement therapy for broad sma population